ZA200901270B - Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-D]-pyridimin-7-ones - Google Patents
Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-D]-pyridimin-7-onesInfo
- Publication number
- ZA200901270B ZA200901270B ZA200901270A ZA200901270A ZA200901270B ZA 200901270 B ZA200901270 B ZA 200901270B ZA 200901270 A ZA200901270 A ZA 200901270A ZA 200901270 A ZA200901270 A ZA 200901270A ZA 200901270 B ZA200901270 B ZA 200901270B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyridimin
- pyrido
- ylamino
- pyridin
- ones
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84305106P | 2006-09-08 | 2006-09-08 | |
US94210407P | 2007-06-05 | 2007-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200901270B true ZA200901270B (en) | 2010-05-26 |
Family
ID=38988315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200901270A ZA200901270B (en) | 2006-09-08 | 2009-02-23 | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-D]-pyridimin-7-ones |
Country Status (15)
Country | Link |
---|---|
US (1) | US7781583B2 (de) |
EP (1) | EP2069344A2 (de) |
JP (1) | JP2008094834A (de) |
KR (1) | KR20090052385A (de) |
CN (1) | CN101511829A (de) |
AR (1) | AR062680A1 (de) |
AU (1) | AU2007297286A1 (de) |
BR (1) | BRPI0716880A2 (de) |
CA (1) | CA2662768A1 (de) |
IL (1) | IL197242A0 (de) |
MX (1) | MX2009002069A (de) |
RU (1) | RU2009108006A (de) |
TW (1) | TW200821309A (de) |
WO (1) | WO2008032157A2 (de) |
ZA (1) | ZA200901270B (de) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL218692B1 (pl) | 2002-01-22 | 2015-01-30 | Warner Lambert Co | Podstawiony 2-(pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-on oraz jego zastosowanie do leczenia zaburzenia lub stanu spowodowanego nieprawidłową proliferacją komórek |
NZ586069A (en) | 2007-12-19 | 2012-05-25 | Amgen Inc | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
US8389533B2 (en) * | 2008-04-07 | 2013-03-05 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
US9294421B2 (en) * | 2009-03-23 | 2016-03-22 | Google Inc. | System and method for merging edits for a conversation in a hosted conversation system |
US9682991B2 (en) | 2009-12-31 | 2017-06-20 | Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii | Tricyclic compounds for use as kinase inhibitors |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
ES2543569T3 (es) | 2011-03-23 | 2015-08-20 | Amgen Inc. | Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3 |
AU2013323360B2 (en) | 2012-09-28 | 2017-09-07 | Cancer Research Technology Limited | Azaquinazoline inhibitors of atypical protein kinase C |
SI3431475T1 (sl) | 2013-02-21 | 2021-08-31 | Pfizer Inc. | Trdne oblike selektivnega zaviralca CDK4/6 |
EP3492470A1 (de) * | 2013-03-15 | 2019-06-05 | Concert Pharmaceuticals, Inc. | Deuteriertes palbociclib mit verbesserter metabolischer stabilität |
CN104470921B (zh) * | 2013-05-17 | 2017-05-03 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
US20170217962A1 (en) * | 2014-07-31 | 2017-08-03 | Sun Pharmaceutical Industries Limited | A process for the preparation of palbociclib |
US20170240543A1 (en) * | 2014-08-14 | 2017-08-24 | Sun Pharmaceutical Industries Limited | Crystalline forms of palbociclib |
EP3186252A1 (de) * | 2014-08-28 | 2017-07-05 | ratiopharm GmbH | Verfahren zur herstellung von palbociclib und pharmazeutische zusammensetzungen damit |
CN105111201B (zh) * | 2014-10-16 | 2017-01-11 | 上海页岩科技有限公司 | 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物 |
CN104447739B (zh) * | 2014-11-07 | 2016-02-17 | 郑州泰基鸿诺药物科技有限公司 | 一种氘代Palbociclib衍生物、制备方法及应用 |
CN104447743B (zh) | 2014-11-26 | 2016-03-02 | 苏州明锐医药科技有限公司 | 帕博西尼的制备方法 |
CN104496983B (zh) * | 2014-11-26 | 2016-06-08 | 苏州明锐医药科技有限公司 | 一种帕博西尼的制备方法 |
WO2016090257A1 (en) * | 2014-12-05 | 2016-06-09 | Crystal Pharmatech Inc. | Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib) |
CN104610254B (zh) * | 2015-01-26 | 2017-02-01 | 新发药业有限公司 | 一种帕博赛布的低成本制备方法 |
SI3255046T1 (sl) * | 2015-02-03 | 2020-02-28 | Jiangsu Hengrui Medicine Co., Ltd. | Hidroksietil sulfonat zaviralca od ciklina odvisne protein-kinaze, njegova kristalinična oblika in postopek priprave le-teh |
CZ201589A3 (cs) * | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
WO2016141881A1 (zh) | 2015-03-11 | 2016-09-15 | 南京明德新药研发股份有限公司 | 作为抗癌药物的取代的2-氢-吡唑衍生物 |
EP3078663A1 (de) | 2015-04-09 | 2016-10-12 | Sandoz Ag | Modifizierte partikel von palbociclib |
WO2016156070A1 (en) | 2015-04-02 | 2016-10-06 | Sandoz Ag | Modified particles of palbociclib |
CN104887641B (zh) * | 2015-04-08 | 2017-12-01 | 上海鲁源医药科技有限公司 | 帕布昔利布胃漂浮片及其制备方法 |
CN104910149A (zh) * | 2015-04-28 | 2015-09-16 | 上海百奇医药科技有限公司 | 一种Palbociclib制备方法 |
CN106117199A (zh) * | 2015-05-04 | 2016-11-16 | 江苏恒瑞医药股份有限公司 | 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法 |
KR102068423B1 (ko) | 2015-06-04 | 2020-01-20 | 화이자 인코포레이티드 | 팔보시클립의 고체 투여 형태 |
CN106317053A (zh) * | 2015-06-29 | 2017-01-11 | 北大方正集团有限公司 | 一种帕博昔布晶型a的制备方法 |
US10526326B2 (en) | 2015-08-05 | 2020-01-07 | Ratiopharm Gmbh | Crystalline form and acetic acid adducts of palbociclib |
CN106474129A (zh) * | 2015-09-01 | 2017-03-08 | 上海方楠生物科技有限公司 | 一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法 |
WO2017036390A1 (zh) * | 2015-09-01 | 2017-03-09 | 上海方楠生物科技有限公司 | 帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法 |
CN106632311B (zh) | 2015-11-02 | 2021-05-18 | 上海科胜药物研发有限公司 | 一种帕博西尼晶型a和晶型b的制备方法 |
CN105418603A (zh) * | 2015-11-17 | 2016-03-23 | 重庆莱美药业股份有限公司 | 一种高纯度帕布昔利布及其反应中间体的制备方法 |
CN106749259B (zh) * | 2015-11-19 | 2019-02-01 | 华东师范大学 | 一种环戊基嘧啶并吡咯类化合物的合成方法 |
CN106831759A (zh) * | 2015-12-03 | 2017-06-13 | 上海星泰医药科技有限公司 | 帕布昔利布及其中间体的制备方法 |
CN105541832A (zh) * | 2015-12-15 | 2016-05-04 | 南京艾德凯腾生物医药有限责任公司 | 一种羟乙基磺酸盐帕布昔利布的制备方法 |
CN106967061A (zh) * | 2016-01-13 | 2017-07-21 | 常州方楠医药技术有限公司 | 帕博西林的盐、晶型及其制备方法 |
CN105949189B (zh) * | 2016-06-05 | 2017-09-22 | 童明琼 | 一种用于治疗乳腺癌的帕博西尼的制备方法 |
CN106083844B (zh) * | 2016-06-05 | 2017-11-10 | 陈志明 | 一种制备抗乳腺癌药物帕博西尼中间体的方法 |
CN105924439B (zh) * | 2016-06-24 | 2017-11-24 | 石家庄海瑞药物科技有限公司 | 一种帕布昔利布的制备方法 |
WO2018007927A1 (en) | 2016-07-04 | 2018-01-11 | Dr. Reddy's Laboratories Limited | Process for preparation of palbociclib |
WO2018009735A1 (en) | 2016-07-07 | 2018-01-11 | Plantex Ltd. | Solid state forms of palbociclib dimesylate |
CN106220627A (zh) * | 2016-07-31 | 2016-12-14 | 合肥远志医药科技开发有限公司 | 一种高纯度帕布昔利布的工业化制备方法 |
SI3497103T1 (sl) | 2016-08-15 | 2021-07-30 | Pfizer Inc. | Zaviralci piridopirimdiona CDK2/4/6 |
WO2018073574A1 (en) | 2016-10-20 | 2018-04-26 | Cipla Limited | Polymorphic forms of palbociclib |
ES2852349T3 (es) | 2016-10-20 | 2021-09-13 | Pfizer | Palbociclib para el tratamiento de PAH |
CN106565707B (zh) * | 2016-11-03 | 2019-01-04 | 杭州科巢生物科技有限公司 | 帕博西尼新合成方法 |
US20190275049A1 (en) | 2016-11-16 | 2019-09-12 | Pfizer Inc. | Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer |
CN108117550B (zh) * | 2016-11-29 | 2020-08-14 | 上海医药工业研究院 | 吡啶并[2,3-d]嘧啶类化合物的制备方法 |
JP7044801B2 (ja) | 2016-12-16 | 2022-03-30 | シーストーン・ファーマスーティカルズ・(スージョウ)・カンパニー・リミテッド | Cdk4/6阻害剤 |
CN108794452B (zh) | 2017-05-05 | 2021-05-28 | 上海时莱生物技术有限公司 | 具有激酶抑制活性的化合物、其制备方法和用途 |
CN109384767B (zh) * | 2017-08-08 | 2020-05-05 | 江苏恒瑞医药股份有限公司 | 一种吡啶并嘧啶类衍生物的制备方法及其中间体 |
EP3700908A1 (de) | 2017-10-27 | 2020-09-02 | Fresenius Kabi Oncology Ltd | Verbessertes verfahren zur herstellung von ribociclib und seinen salzen |
CN107759596A (zh) * | 2017-12-05 | 2018-03-06 | 安庆奇创药业有限公司 | 一种合成帕博西尼的方法 |
CN108586452A (zh) * | 2018-01-12 | 2018-09-28 | 重庆市碚圣医药科技股份有限公司 | 一种帕博西尼中间体的合成方法 |
CN108283940B (zh) * | 2018-01-22 | 2021-01-29 | 重庆华邦制药有限公司 | 帕布昔利布中间体的制备方法 |
US20200405809A1 (en) | 2018-02-27 | 2020-12-31 | Pfizer Inc. | Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor |
CN108299422B (zh) * | 2018-02-28 | 2019-10-25 | 杭州福斯特药业有限公司 | 一种帕泊昔利布中间体的制备方法 |
HUE064843T2 (hu) | 2018-05-14 | 2024-04-28 | Pfizer | Orális oldat kiszerelés |
JP6952747B2 (ja) | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのTGFβ阻害剤およびCDK阻害剤の組合せ |
US20220125777A1 (en) | 2019-02-01 | 2022-04-28 | Pfizer Inc. | Combination of a cdk inhibitor and a pim inhibitor |
CN109721547A (zh) * | 2019-02-11 | 2019-05-07 | 陈欣 | 一种治疗乳腺癌药物帕博西尼的中间体的制备方法 |
EP3976043A1 (de) | 2019-05-24 | 2022-04-06 | Pfizer Inc. | Kombinationstherapien mit cdk-hemmern |
EP3976090A1 (de) | 2019-05-24 | 2022-04-06 | Pfizer Inc. | Kombinationstherapien mit cdk-hemmern |
CN110143948B (zh) * | 2019-06-21 | 2021-05-14 | 上海博悦生物科技有限公司 | Cdk4/6抑制剂、其药物组合物、制备方法及应用 |
CN112920182B (zh) * | 2019-12-05 | 2023-08-01 | 上海天慈国际药业有限公司 | 一种帕布昔利布的制备方法 |
TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
BR112023000687A2 (pt) | 2020-07-15 | 2023-02-07 | Pfizer | Métodos e combinações de inibidores de kat6 para o tratamento de câncer |
EP4181919A1 (de) | 2020-07-20 | 2023-05-24 | Pfizer Inc. | Kombinationstherapie |
WO2022091001A1 (en) | 2020-10-29 | 2022-05-05 | Pfizer Ireland Pharmaceuticals | Process for preparation of palbociclib |
CN112457311B (zh) * | 2020-12-04 | 2022-07-12 | 江苏豪森药业集团有限公司 | 一种含有氯溴吡咯嘧啶酮结构化合物的制备方法 |
WO2022123419A1 (en) | 2020-12-08 | 2022-06-16 | Pfizer Inc. | Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib |
CN112552297A (zh) * | 2020-12-12 | 2021-03-26 | 江西国药有限责任公司 | 一种哌柏西利的制备方法与流程 |
CN112661753B (zh) * | 2020-12-29 | 2022-06-03 | 山东铂源药业股份有限公司 | 一种帕布昔利布中间体的制备方法 |
CN112898299B (zh) * | 2021-01-26 | 2021-11-26 | 山东铂源药业有限公司 | 一种帕布昔利布中间体的制备方法 |
CN113683612B (zh) * | 2021-09-07 | 2022-06-17 | 山东铂源药业股份有限公司 | 一种帕布昔利布的制备方法 |
AU2022408062A1 (en) | 2021-12-10 | 2024-06-20 | Eli Lilly And Company | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor |
WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
WO2023114264A1 (en) | 2021-12-15 | 2023-06-22 | Eli Lilly And Company | Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer |
WO2024023703A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
WO2024049926A1 (en) | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
WO2024097206A1 (en) | 2022-11-02 | 2024-05-10 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
CN116283969A (zh) * | 2023-02-24 | 2023-06-23 | 杭州新曦科技有限公司 | 用于制备帕博西尼及其相关中间体的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL218692B1 (pl) * | 2002-01-22 | 2015-01-30 | Warner Lambert Co | Podstawiony 2-(pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-on oraz jego zastosowanie do leczenia zaburzenia lub stanu spowodowanego nieprawidłową proliferacją komórek |
RU2317296C2 (ru) * | 2003-07-11 | 2008-02-20 | Уорнер-Ламберт Компани Ллс | Изетионатная соль селективного ингибитора cdk4 |
-
2007
- 2007-08-27 CA CA002662768A patent/CA2662768A1/en not_active Abandoned
- 2007-08-27 RU RU2009108006/04A patent/RU2009108006A/ru not_active Application Discontinuation
- 2007-08-27 MX MX2009002069A patent/MX2009002069A/es not_active Application Discontinuation
- 2007-08-27 CN CNA2007800334161A patent/CN101511829A/zh active Pending
- 2007-08-27 WO PCT/IB2007/002524 patent/WO2008032157A2/en active Application Filing
- 2007-08-27 KR KR1020097007146A patent/KR20090052385A/ko not_active Application Discontinuation
- 2007-08-27 AU AU2007297286A patent/AU2007297286A1/en not_active Abandoned
- 2007-08-27 EP EP07804871A patent/EP2069344A2/de not_active Withdrawn
- 2007-08-27 BR BRPI0716880-2A2A patent/BRPI0716880A2/pt not_active IP Right Cessation
- 2007-09-06 AR ARP070103937A patent/AR062680A1/es not_active Application Discontinuation
- 2007-09-07 JP JP2007232730A patent/JP2008094834A/ja not_active Withdrawn
- 2007-09-07 TW TW096133457A patent/TW200821309A/zh unknown
- 2007-09-10 US US11/852,873 patent/US7781583B2/en not_active Expired - Fee Related
-
2009
- 2009-02-23 ZA ZA200901270A patent/ZA200901270B/xx unknown
- 2009-02-25 IL IL197242A patent/IL197242A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20080125588A1 (en) | 2008-05-29 |
BRPI0716880A2 (pt) | 2013-10-15 |
TW200821309A (en) | 2008-05-16 |
IL197242A0 (en) | 2009-12-24 |
US7781583B2 (en) | 2010-08-24 |
AR062680A1 (es) | 2008-11-26 |
AU2007297286A1 (en) | 2008-03-20 |
EP2069344A2 (de) | 2009-06-17 |
KR20090052385A (ko) | 2009-05-25 |
CN101511829A (zh) | 2009-08-19 |
WO2008032157A2 (en) | 2008-03-20 |
RU2009108006A (ru) | 2010-10-20 |
WO2008032157A3 (en) | 2008-10-23 |
MX2009002069A (es) | 2009-03-06 |
CA2662768A1 (en) | 2008-03-20 |
JP2008094834A (ja) | 2008-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200901270B (en) | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-D]-pyridimin-7-ones | |
DK3872059T3 (en) | Process for the preparation of 2,3,3,3 tetrahydrofluoropropene | |
IL196875A0 (en) | Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines | |
IL198847A0 (en) | New process for the preparation of 2-imino-thiazolidin-4-one derivatives | |
HK1133654A1 (en) | Pyridin-4-yl derivatives as immunomodulating agents | |
HK1135976A1 (en) | Pyridin-3-yl derivatives as immunomodulating agents | |
ZA200903533B (en) | Process for the preparation of rosuvastatin | |
HRP20130626T1 (en) | Pyridinone compounds | |
EP2136810A4 (de) | Neuartige 1,8-naphthyridinverbindungen | |
PL1874746T3 (pl) | Pochodne 1-N-azacykloalkilo-3-fenoksypropanu użyteczne do wytwarzania leków psychotropowych | |
EP2205611A4 (de) | Verfahren zur herstellung von prasugrel sowie salzen und polymeren daraus | |
ZA201000127B (en) | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors | |
PL2124944T3 (pl) | Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy | |
ZA200906648B (en) | Pyrido [2,3-D] pyramidin-7-one compounds as inhibitors of P13K-alpha for the treatment of cancer | |
IL210074A (en) | Process for the preparation of pyrido derivatives [2, 3 – d] pyrimidine-7-il-phenyl | |
IL194549A0 (en) | 2-(pyridin-2-yl)-pyrimidines for use as fungicides | |
HK1122797A1 (en) | Derivatives of pyrido | |
HK1144682A1 (en) | Process for the preparation of alkyl 3,3-dialkoxypropionates 33- | |
IL205082A0 (en) | Process for the preparation of tetranorlabdane derivatives | |
EP2083003A4 (de) | Verfahren zur herstellung von 1,1,1,3,3-pentachlorbutan | |
EP1996192A4 (de) | Verfahren zur herstellung von 3,4-disubstituierten thiazolidin-2-onen | |
ZA201001727B (en) | "alkylsulfone derivatives" | |
IL182657A0 (en) | A process for the preparation of pyridine compounds | |
ZA201003264B (en) | Method for the preparation of 2 chloro1,1,1,2,3,3,3 heptafluopropane | |
PL2076521T3 (pl) | Sposób otrzymywania sililopodstawionych 1,2 alkinów |